Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure.

Kurdi, Hibba; Shah, Parin; Barker, Simon; Harris, Daniel; Dicken, Benjamin; Edwards, Carey; Jenkins, Geraint

Kurdi, Hibba; Shah, Parin; Barker, Simon; Harris, Daniel; Dicken, Benjamin; Edwards, Carey; Jenkins, Geraint.

Afiliación

Kurdi H; Specialty Trainee in Cardiology Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Shah P; Specialty Trainee in Cardiology Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Barker S; Internal Medicine Trainee Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Harris D; Cardiac Pharmacist Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Dicken B; Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Edwards C; Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.
Jenkins G; Consultant Cardiologist Regional Cardiac Centre, Morriston Hospital, Morriston, Swansea, SA6 6NL.

Br J Cardiol ; 28(2): 18, 2021.

Article en En | MEDLINE | ID: mdl-35747454

Palabras clave

acute heart failure; dapagliflozin; heart failure with reduced ejection fraction; sodium-glucose co-transport 2 (SGLT2) inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Br J Cardiol Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google